Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Drop in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 21,100 shares, a decline of 86.8% from the October 15th total of 159,900 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 15,490,000 shares, the days-to-cover ratio is currently 0.0 days.

Bluejay Diagnostics Stock Performance

NASDAQ BJDX opened at $0.10 on Thursday. The business’s 50 day moving average price is $0.12 and its 200-day moving average price is $1.39. Bluejay Diagnostics has a fifty-two week low of $0.07 and a fifty-two week high of $31.28. The company has a market cap of $1.72 million, a P/E ratio of 0.00 and a beta of 0.73.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($5.12) earnings per share for the quarter.

Institutional Investors Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. CVI Holdings LLC bought a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 66,165 shares of the company’s stock, valued at approximately $46,000. CVI Holdings LLC owned about 19.69% of Bluejay Diagnostics at the end of the most recent quarter. Institutional investors and hedge funds own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.